Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients ; volume:4 ; number:1 ; day:16 ; month:8 ; year:2006 ; pages:1-11 ; date:6.2006
Journal of translational medicine ; 4, Heft 1 (16.8.2006), 1-11, 6.2006
- Urheber
-
Ridolfi, Ruggero
- Beteiligte Personen und Organisationen
-
Petrini, Massimiliano
Fiammenghi, Laura
Stefanelli, Monica
Ridolfi, Laura
Ballardini, Michela
Migliori, Giuseppe
Riccobon, Angela
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-4-36
- URN
-
urn:nbn:de:1111-2016041431213
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ridolfi, Ruggero
- Petrini, Massimiliano
- Fiammenghi, Laura
- Stefanelli, Monica
- Ridolfi, Laura
- Ballardini, Michela
- Migliori, Giuseppe
- Riccobon, Angela
- SpringerLink (Online service)
Ähnliche Objekte (12)
Improved dendritic cell vaccination for combined melanoma immune therapy
Improved dendritic cell vaccination for combined melanoma immune therapy
Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
Current status of dendritic cell-based tumor vaccination
S43. Dendritic cell vaccination combined with CTLA4 blockade
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
P55. Dendritic cell vaccination for postremission therapy in AML
Mechanism of dendritic cell-based vaccination against Leishmania major
Improved dendritic cell vaccination for combined melanoma immune therapy
Improved dendritic cell vaccination for combined melanoma immune therapy
Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
Current status of dendritic cell-based tumor vaccination
S43. Dendritic cell vaccination combined with CTLA4 blockade
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
P55. Dendritic cell vaccination for postremission therapy in AML
Mechanism of dendritic cell-based vaccination against Leishmania major
Improved dendritic cell vaccination for combined melanoma immune therapy
Improved dendritic cell vaccination for combined melanoma immune therapy
Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
Current status of dendritic cell-based tumor vaccination
S43. Dendritic cell vaccination combined with CTLA4 blockade
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
P55. Dendritic cell vaccination for postremission therapy in AML